Published in Mem Inst Oswaldo Cruz on January 20, 2003
Lutzomyia longipalpis urbanisation and control. Mem Inst Oswaldo Cruz (2015) 0.85
Application of Recombinant Proteins for Serodiagnosis of Visceral Leishmaniasis in Humans and Dogs. Iran Biomed J (2016) 0.75
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
On the origin of leprosy. Science (2005) 4.22
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol (2004) 2.56
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One (2011) 2.39
Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09
Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol (2002) 2.05
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med (2010) 2.00
Second-generation vaccines against leishmaniasis. Trends Parasitol (2005) 1.99
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun (2004) 1.90
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 1.70
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2012) 1.62
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine (2009) 1.60
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine (2009) 1.58
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. Clin Diagn Lab Immunol (2002) 1.54
Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med (2011) 1.53
Adjuvants for cancer vaccines. Semin Immunol (2010) 1.48
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces (2009) 1.47
Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol (2007) 1.45
The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am J Trop Med Hyg (2002) 1.43
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun (2002) 1.42
The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol (2012) 1.39
Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine (2009) 1.39
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun (2007) 1.34
Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLoS Negl Trop Dis (2010) 1.28
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine (2002) 1.28
Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun (2006) 1.27
Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun (2005) 1.26
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release (2013) 1.25
Adjuvants for human vaccines. Curr Opin Immunol (2012) 1.25
Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun (2006) 1.23
GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis (2011) 1.22
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One (2012) 1.22
Molecular and enzymatic analysis of ammonium assimilation in woody plants. J Exp Bot (2002) 1.21
Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop (2003) 1.20
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value. Clin Vaccine Immunol (2010) 1.19
Immunological dominance of Trypanosoma cruzi tandem repeat proteins. Infect Immun (2008) 1.18
Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry (2002) 1.16
Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A (2012) 1.14
Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol (2010) 1.14
Potential serological use of a recombinant protein that is a replica of a Mycobacterium tuberculosis protein found in the urine of infected mice. Clin Diagn Lab Immunol (2004) 1.13
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine (2011) 1.13
Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem (2010) 1.12
Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis (2006) 1.12
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine (2009) 1.12
ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy. Clin Vaccine Immunol (2006) 1.11
Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins. Infect Immun (2006) 1.09
Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine (2007) 1.09
Functional interactions between a glutamine synthetase promoter and MYB proteins. Plant J (2004) 1.07
De novo assembly of maritime pine transcriptome: implications for forest breeding and biotechnology. Plant Biotechnol J (2013) 1.06
Rapid quantitative serological test for detection of infection with Mycobacterium leprae, the causative agent of leprosy. J Clin Microbiol (2013) 1.06
Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B Biointerfaces (2008) 1.06
Ammonium assimilation and amino acid metabolism in conifers. J Exp Bot (2007) 1.05
HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine (2013) 1.03
MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant. Eur J Immunol (2013) 1.03
The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine (2011) 1.03
Up-regulation and localization of asparagine synthetase in tomato leaves infected by the bacterial pathogen Pseudomonas syringae. Plant Cell Physiol (2004) 1.02
The glutamine synthetase gene family in Populus. BMC Plant Biol (2011) 1.02
KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol (2011) 1.01
Cloning of the gene encoding a protective Mycobacterium tuberculosis secreted protein detected in vivo during the initial phases of the infectious process. J Immunol (2005) 1.01
Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem (2002) 1.00
Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin Vaccine Immunol (2012) 1.00
Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. FEMS Immunol Med Microbiol (2009) 0.99
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev (2003) 0.99
Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays. Oncogene (2002) 0.98
Organ-specific immunity in canine visceral leishmaniasis: analysis of symptomatic and asymptomatic dogs naturally infected with Leishmania chagasi. Am J Trop Med Hyg (2004) 0.98
Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis (2011) 0.98
Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine (2010) 0.98
Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun (2011) 0.97
Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs. Vet Parasitol (2008) 0.97
Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate (2004) 0.97
Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis. Clin Vaccine Immunol (2008) 0.96
Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS (2010) 0.96
Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine (2011) 0.96
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ. Eur J Immunol (2014) 0.96
Development of a quantitative rapid diagnostic test for multibacillary leprosy using smart phone technology. BMC Infect Dis (2013) 0.95
Upregulated expression of B-cell antigen family tandem repeat proteins by Leishmania amastigotes. Infect Immun (2010) 0.95
Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon. Infect Immun (2009) 0.94
Interruption of Onchocerca volvulus transmission in Northern Venezuela. Parasit Vectors (2013) 0.93
A Myb transcription factor regulates genes of the phenylalanine pathway in maritime pine. Plant J (2013) 0.93
Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. Am J Trop Med Hyg (2010) 0.93
EuroPineDB: a high-coverage web database for maritime pine transcriptome. BMC Genomics (2011) 0.92
TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses. Vaccine (2013) 0.92
Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine (2012) 0.92
Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine (2012) 0.92
Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis. Clin Vaccine Immunol (2009) 0.92
Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine (2010) 0.92
Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol (2012) 0.92
Application of an improved enzyme-linked immunosorbent assay method for serological diagnosis of canine leishmaniasis. J Clin Microbiol (2010) 0.92
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine (2011) 0.91
KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. PLoS Negl Trop Dis (2012) 0.91
Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz (2004) 0.91
Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay. J Immunol Methods (2011) 0.91
Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report. Int J Dermatol (2006) 0.90
Antigen-specific T-cell responses of leprosy patients. Clin Vaccine Immunol (2008) 0.90
Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection. Vaccine (2009) 0.90